The Effect of Berberine on Polycystic Ovary Syndrome Patients with Insulin Resistance (PCOS-IR): A Meta-Analysis and Systematic Review

Table 1

The essential information of trials included in the meta-analysis.

No.	Trials	Comparisons	Sample size	Protocol	Duration	Outcomes
1	KUANG Heng (2014) [10]	BBR/MET	23/28	BBR:300mg tid/	3 months	BMI, WHR, FSH, LH, LH/FSH, T, HOMA-IR, TC, TG, HDL-C, LDL-C
				MET:500mg bid
2	AN Yuan et al. (2014) (2016)[11, 12]	BBR/MET/P	44/41/43	BBR: 500mg tid/	3 months	BMI, WHR, FSH, LH, T, HOMA-IR, FBG, FIN, TC, TG, HDL-C, LDL-C
				MET: 500mg tid/
				P: 1 tablet tid
3	LI Xiaobin e-t al. (2017) [13]	BBR/MET	26/29	BBR:300mg tid/	3 months	BMI, HOMA-IR, FSH, LH, LH/FSH, T, FPG, FIN, TC, TG, HDL-C, LDL-C
				MET:500mg bid
4	WANG Ling-xiao et al. (2011) [14]	MET+BBR/MET	28/28	MET:500mg tid +BBR:500mg tid /MET:500mg tid	3 months	BMI, LH, FSH, LH/FSH, T, FBS, FIN, HOMA-IR
5	WANG Ping et al(2016) [15]	MET+BBR/MET	42/42	MET:500mg tid +BBR:500mg tid /MET:500mg tid	3 months	BMI, WHR, FSH, LH, LH/FSH, HOMA-IR, T,
6	MA Yukun e-t al. (2011) [4]	CPA+BBR/CPA/CPA+BBR; +MET/ CPA+MET	31/28/33/30	CPA:1 tablet qd+BBR:500mg bid/; CPA:1 tablet qd /	3 months	BMI, WHR, FPG, FIN, HOMA-IR, TC, TG, HDL-C, LDL-C, FSH, T, LH
				CPA:1 tablet qd +BBR:500mg bid+MET:500mg tid
				CPA:1 tablet qd +MET:500mg tid
7	WEI Wei et al.(2012) [16]	CPA+BBR/ CPA+MET/CPA +P	31/30/28	CPA 1 tablet qd+BBR:500mg tid /	3 months	BMI, WHR, FPG, FIN, HOMA-IR, TC, TG, HDL-C, LDL-C
				CPA 1 tablet qd +MET:500mg tid /
				CPA 1 tablet qd + P:1 tablet bid
8	ZHU Qiuyan et al. (2016) [17]	CPA+BBR/	25/25	CPA 1 tablet qd +BBR:300mg tid /; CPA 1 tablet qd + P: 1 tablet tid	3 months	BMI, WHR, FPG, HOMA-IR, TC, TG FSH, LH, T
		CPA +P
9	CHEN Xiao et al.(2016) [18]	CPA+BBR/	50/50	CPA 1 tablet qd +BBR:500mg bid /; CPA 1 tablet qd	3 months	TC, TG, HDL-C, LDL-C, FPG, FIN
		CPA

Notes: BBR: berberine; MET: metformin; CPA: cyproterone acetate; P: placebo; qd: once a day; bid: twice a day; tid: three times a day.
BMI: body mass index; FSH: follicle-stimulating hormone; LH: luteinizing hormone; T: testosterone; HOMA-IR: homeostasis model assessment of insulin resistance; TC: total cholesterol; TG: triacylglycerol; DLD-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; WHR: waist hip rate; FIN: fasting insulin; FPG: fasting blood glucose.